Pan­cre­at­ic can­cer com­bo sees high sur­vival rates in Chemo­Cen­tryx PhIb da­ta

A Moun­tain View com­pa­ny is post­ing ear­ly da­ta from a pan­cre­at­ic can­cer drug pro­gram, in which its im­munother­a­py and chemother­a­py com­bo sig­nif­i­cant­ly out­per­formed chemo on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER